Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 3 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

6 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Tristan Manalac, 4 days ago
The risk of complicated appendicitis is lower in children with IgE-mediated allergy, according to a recent study.

Ranolazine does not lower incidence of first VT/VF, death in high-risk ICD patients

09 Aug 2018
The implantable cardioverter defibrillator (ICD) is a small device implanted under the skin in the chest, to help control life-threatening arrhythmias.

Ranolazine has failed to significantly reduce the incidence of the first ventricular tachycardia (VT) or ventricular fibrillation (VF) or death in high-risk patients with implantable cardioverter-defibrillators (ICDs), a recent study has found. However, this study is underpowered to detect a difference in the primary endpoint.

Moreover, prespecified secondary endpoint analyses reveal an association between ranolazine administration and a significant reduction in recurrent VT or VF requiring ICD therapy without evidence for increased mortality.

This double-blind, placebo-controlled clinical trial randomized high-risk ICD patients with ischaemic or nonischaemic cardiomyopathy to 1,000-mg ranolazine twice a day or placebo. VT or VF requiring appropriate ICD therapy or death, whichever occurred first, was the primary endpoint. Prespecified secondary endpoints included ICD shock for VT, VR or death and current VT or VR requiring ICD therapy.

A total of 1,012 ICD patients (mean age 64 years; 18 percent women) were included in the trial (ranolazine, n=510; placebo, n=502). The primary endpoint occurred in 372 (37 percent) patients during 28 months of follow-up. There were 270 (27 percent) VT or VF cases and 148 (15 percent) deaths.

A total of 199 (39.6 percent) patients receiving placebo and 253 (49.6 percent) patients on ranolazine discontinued treatment (p=0.001). The hazard ratio (HR) for VT, VF or death with ranolazine vs placebo was 0.84 (95 percent CI, 0.67–1.05; p=0.117).

Based on a prespecified secondary analysis, patients on ranolazine had a marginally significant lower risk of ICD therapies for recurrent VT or VF (HR, 0.70; 0.51–0.96; p=0.028). No other significant treatment effects were noted in other prespecified secondary analyses, including components of the primary endpoint, inappropriate shocks, cardiac hospitalizations and quality of life.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 3 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

6 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Tristan Manalac, 4 days ago
The risk of complicated appendicitis is lower in children with IgE-mediated allergy, according to a recent study.